Systematic review reveals variable efficacy among medical and procedural therapies for radiation-induced fibrosis in head and neck cancer, highlighting the need for standardized trials.
OBJECTIVE: To review and evaluate treatments for radiation-induced fibrosis (RIF) following head and neck cancer (HNC) therapy. DATA SOURCES: Medline, Embase.com, Web of Science, and Cochrane Library. REVIEW METHODS: A systematic review was conducted on the management of HNC RIF using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Descriptive synthesis was conducted to summarize treatment efficacy. RESULTS: After initial screening of 4078 titles and abstracts, 147 full-text articles were reviewed, with eight meeting inclusion criteria. Pharmacological interventions included pentoxifylline-tocopherol, pravastatin, amifostine, and topical superoxide dismutase (SOD). Pentoxifylline-tocopherol, pravastatin, and amifostine demonstrated variable fibrosis improvement rates across studies. In one uncontrolled trial, 83% of patients receiving pentoxifylline-tocopherol achieved ≥50% reduction in measured fibrotic surface area, and pravastatin reduced fibrosis thickness by ≥30% in 35.7% of patients. Procedural interventions included lipotransfer and microcurrent therapy, with lipotransfer associated with physical improvements in 97% of patients (n = 38) and microcurrent therapy enhancing cervical mobility in 92% of patients (n = 26). CONCLUSION: Improvements in HNC fibrosis after current treatments ranged widely across studies; however, substantial heterogeneity in study design and outcome measurement limits definitive conclusions regarding comparative effectiveness.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: